IN2014MN00377A - - Google Patents

Download PDF

Info

Publication number
IN2014MN00377A
IN2014MN00377A IN377MUN2014A IN2014MN00377A IN 2014MN00377 A IN2014MN00377 A IN 2014MN00377A IN 377MUN2014 A IN377MUN2014 A IN 377MUN2014A IN 2014MN00377 A IN2014MN00377 A IN 2014MN00377A
Authority
IN
India
Prior art keywords
complex
metalloproteinase inhibitor
relates
renal
kda
Prior art date
Application number
Inventor
Joseph Anderberg
Jeff Gray
Paul Mcpherson
Kevin Nakamura
James Patrick Kampf
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of IN2014MN00377A publication Critical patent/IN2014MN00377A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Abstract

The present invention relates to methods and compositions for monitoring diagnosis prognosis and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Heat shock 70 kDa protein 1 Alpha 1 antitrypsin Neutrophil elastase complex Stromelysin 1 :Metalloproteinase inhibitor 2 complex 72 kDa type IV collagenase: Metalloproteinase inhibitor 2 complex Insulin like growth factor 1 receptor Myeloid differentiation primary response protein MyD88 Neuronal cell adhesion molecule and Tumor necrosis factor ligand superfamily member 10 as diagnostic and prognostic biomarkers in renal injuries.
IN377MUN2014 2011-08-26 2012-08-24 IN2014MN00377A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161528003P 2011-08-26 2011-08-26
US201161528000P 2011-08-26 2011-08-26
PCT/US2012/052298 WO2013043310A1 (en) 2011-08-26 2012-08-24 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
IN2014MN00377A true IN2014MN00377A (en) 2015-06-19

Family

ID=47914751

Family Applications (1)

Application Number Title Priority Date Filing Date
IN377MUN2014 IN2014MN00377A (en) 2011-08-26 2012-08-24

Country Status (16)

Country Link
US (2) US9459261B2 (en)
EP (2) EP2748605B1 (en)
JP (2) JP2014529073A (en)
KR (1) KR20140074307A (en)
CN (2) CN106443011A (en)
AU (1) AU2012312907A1 (en)
BR (1) BR112014004389A2 (en)
CA (1) CA2846602A1 (en)
EA (1) EA201490384A1 (en)
ES (1) ES2721907T3 (en)
IN (1) IN2014MN00377A (en)
MX (1) MX346096B (en)
PL (1) PL2748605T3 (en)
PT (1) PT2748605T (en)
TR (1) TR201903235T4 (en)
WO (1) WO2013043310A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102246035B (en) 2008-10-21 2014-10-22 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104698161A (en) 2009-12-20 2015-06-10 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20140074307A (en) * 2011-08-26 2014-06-17 아스튜트 메디컬 인코포레이티드 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2788759B1 (en) 2011-12-08 2019-02-20 Astute Medical, Inc. Methods and uses for diagnosis of renal injury and renal failure
CA3158996A1 (en) 2013-01-17 2014-07-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11261257B2 (en) 2013-01-28 2022-03-01 Diasorin S.P.A. Methods for detecting 1,25-dihydroxyvitamin D and related antibodies
PL2759550T3 (en) 2013-01-28 2019-01-31 Diasorin S.P.A. Method and kit for detecting 1,25-dihydroxyvitamin D and related antibodies
US10983136B2 (en) * 2013-01-28 2021-04-20 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker
CN110007084B (en) 2013-12-03 2022-11-18 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
PT3210018T (en) * 2014-10-20 2021-10-04 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2016113719A1 (en) * 2015-01-18 2016-07-21 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin d values in ratio with pth as a prognostic biomarker
EP3281011A4 (en) 2015-04-09 2018-11-21 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105466984B (en) * 2016-01-14 2018-12-28 郑以山 Prior-warning device and its application method for the non-explicit damage of kidney
US11243217B2 (en) 2016-06-06 2022-02-08 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
EP3568695A4 (en) 2017-01-12 2020-12-16 Astute Medical, Inc. Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement
EP3577458A4 (en) 2017-02-06 2021-04-07 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11718682B2 (en) 2017-04-05 2023-08-08 Astute Medical, Inc. Assays for TIMP2 having improved performance in biological samples
KR20210019459A (en) 2018-05-24 2021-02-22 레니버스 테라퓨틱스, 인크. How to treat people at risk for kidney damage and kidney failure
CN109251956A (en) * 2018-09-18 2019-01-22 青岛大学 The adjustment effect of MyD88 mRNA expression and Radix Astragali in diabetes rat pancreas islet
US20220178946A1 (en) * 2018-11-02 2022-06-09 Prevencio, Inc. Prognostic and diagnostic methods for risk of acute kidney injury
CN114113575B (en) * 2020-08-28 2023-06-02 菲鹏生物股份有限公司 Labeling compound and preparation method and application thereof
CN116434960B (en) * 2023-06-13 2023-10-13 中国人民解放军总医院 Cardiogenic shock clinical decision support system, equipment and storable medium

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
JPH05504841A (en) 1990-09-14 1993-07-22 バイオサイト・ダイアグノスティックス・インコーポレイテッド Antibodies against ligand receptors and ligand complexes and their use in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
ATE177841T1 (en) 1991-04-10 1999-04-15 Biosite Diagnostics Inc CROSSTALK OR CROSSTALK INHIBITORS AND THEIR USE
CA2107899A1 (en) 1991-04-10 1992-10-11 Gunars Edwin Valkirs Novel conjugates and assays for simultaneous detection of multiple ligands
US5324634A (en) * 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
DE602004022150D1 (en) 2003-03-27 2009-09-03 Childrens Hosp Medical Center METHOD AND KIT FOR IDENTIFYING THE EARLY STAGE OF A NIERENTUBULUS CELL INJURY
CN1791797A (en) * 2003-03-27 2006-06-21 儿童医院医疗中心 A method and kit for detecting the early onset of renal tubular cell injury
US7560244B2 (en) * 2003-06-04 2009-07-14 Joslin Diabetes Center, Inc. Method of evaluating a subject for risk or predisposition of reduced renal function over time
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US20060003345A1 (en) * 2004-06-30 2006-01-05 Pfizer Inc RNA bioassay
CN101557825A (en) * 2005-08-19 2009-10-14 森托科尔公司 Proteolysis resistant antibody preparations
WO2007144781A2 (en) * 2006-04-21 2007-12-21 Diagnotech Pty. Ltd. Diagnostic methods and kits utilizing antibodies for metalloproteases
ES2532220T3 (en) * 2007-03-26 2015-03-25 Novartis Ag Biomarkers of predictive renal safety and biomarker signals to monitor renal function
PL2215481T5 (en) * 2007-11-15 2017-10-31 Bioporto Diagnostics As Diagnostic use of individual molecular forms of a biomarker
WO2009107384A1 (en) * 2008-02-29 2009-09-03 国立大学法人名古屋大学 Biomarker for the estimation of acute renal disorder and prognosis of the disorder, and use of the biomarker
MX341926B (en) * 2008-08-28 2016-09-07 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure.
EP2813848A3 (en) * 2008-08-29 2015-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102246035B (en) * 2008-10-21 2014-10-22 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010054389A1 (en) * 2008-11-10 2010-05-14 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) * 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20120129265A1 (en) * 2009-06-02 2012-05-24 Biocrates Life Sciences Ag New biomarkers for assessing kidney diseases
CA2770393A1 (en) * 2009-08-07 2011-02-10 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3299821A1 (en) * 2009-09-18 2018-03-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2009012633A (en) 2009-11-23 2011-05-24 Univ Mexico Nacional Autonoma Diagnostic method for detecting acute kidney injury using heat shock protein 72 as a sensitive biomarker.
CN104698161A (en) * 2009-12-20 2015-06-10 阿斯图特医药公司 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ602056A (en) * 2010-02-26 2014-11-28 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20140074307A (en) * 2011-08-26 2014-06-17 아스튜트 메디컬 인코포레이티드 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Also Published As

Publication number Publication date
MX2014002146A (en) 2014-08-21
US20170016917A1 (en) 2017-01-19
US9459261B2 (en) 2016-10-04
KR20140074307A (en) 2014-06-17
CN103874923B (en) 2016-09-14
US9784750B2 (en) 2017-10-10
BR112014004389A2 (en) 2017-03-28
ES2721907T3 (en) 2019-08-06
US20140213477A1 (en) 2014-07-31
EP3489690A1 (en) 2019-05-29
CN106443011A (en) 2017-02-22
JP2017032586A (en) 2017-02-09
NZ706242A (en) 2016-07-29
CN103874923A (en) 2014-06-18
CA2846602A1 (en) 2013-03-28
JP2014529073A (en) 2014-10-30
EA201490384A1 (en) 2014-08-29
PL2748605T4 (en) 2019-08-30
EP2748605B1 (en) 2018-12-05
TR201903235T4 (en) 2019-03-21
MX346096B (en) 2017-03-07
PT2748605T (en) 2019-05-03
AU2012312907A1 (en) 2014-03-13
PL2748605T3 (en) 2019-08-30
NZ621716A (en) 2016-04-29
EP2748605A4 (en) 2015-12-02
WO2013043310A1 (en) 2013-03-28
EP2748605A1 (en) 2014-07-02

Similar Documents

Publication Publication Date Title
IN2014MN00377A (en)
MX2011002233A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure.
EA201290629A1 (en) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PREDICTION OF KIDNEY DAMAGE AND RENAL FAILURE
WO2011106746A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012174282A3 (en) Biomarker compositions and methods
NZ592358A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure using tissue inhibitor of metalloproteinase 2 (timp-2)
MX342967B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure.
BR112014002975A2 (en) biomarker compositions and methods
WO2009024691A3 (en) Method of assaying leukocyte elastase inhibitor for the in vitro diagnosis of colorectal cancer
EP2585827A4 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX361944B (en) Methods for detecting signatures of disease or conditions in bodily fluids.
MX2014000283A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure.
TN2013000358A1 (en) Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
NZ619883A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2008100352A3 (en) Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis
MX2012001559A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure.
EA201290192A1 (en) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PREDICTION OF KIDNEY DAMAGE AND RENAL FAILURE
EA201290195A1 (en) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PREDICTION OF KIDNEY DAMAGE AND RENAL FAILURE
MX2019008260A (en) Methods and compositions for evaluation and treatment of renal injury and renal failure based on c-c motif chemokine ligand 14 measurement.
WO2009019370A3 (en) Apolipoprotein aii assay method for the in vitro diagnosis of colorectal cancer
MX339765B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure.
IN2014MN00949A (en)
MX2012003168A (en) Methods and composition for diagnosis and prognosis of renal injury and renal failure.
IN2014MN01759A (en)
BR112015021507A2 (en) methods and compositions for the diagnosis of preeclampsia